Krsnaa Diagnostics Limited has informed the Exchange about Investor Presentation
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krsnaa Diagnostics reported Q1 FY26 revenue of ₹1,930 million, up 13% year-on-year, with EBITDA rising 19% to ₹524 million and margin expanding 120 basis points to 27%. Profit after tax grew 15% to ₹205 million, with EPS at ₹6.3. The company served about 5 million patients and performed nearly 16 million tests during the quarter. The retail business is scaling rapidly, with touch points jumping from 362 to 2,414 and retail revenue rising from ₹15 million to ₹118 million, with the B2C share of retail revenue climbing to 66% from 10%. Management highlighted that the existing order book, including the Rajasthan project, will expand the network to 200+ CT/MRI centres, 7 reference labs, 41 mother labs, 249 satellite labs and over 5,000 collection centres, with retail exclusive centres targeted to grow to 700 by FY27.
Margin expansion of 120 basis points in EBITDA and strong retail growth signal improving profitability and diversification beyond government contracts, which may be viewed positively by investors. The multi-year network expansion targets through FY27 suggest a clear growth runway, though execution of the large order book remains a key monitorable.